01770nas a2200337   4500000000100000008004100001260001300042653000900055653002600064653001600090653001400106653003000120653002200150653001100172653002300183653001200206653000900218653001600227653001600243653001400259653001300273653001700286653002200303100001200325700001500337245007800352300001100430490000700441520097000448022001401418       2007                            d  c2007 Sep10aAged10aAnti-Bacterial Agents10aClofazimine10aCystamine10aDrug Therapy, Combination10aFollow-Up Studies10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aMinocycline10aOfloxacin10aRifampin10aTime Factors10aTreatment Outcome1 aOzaki M1 aIshikawa M00a[Long-term follow-up of ofloxacin-combined therapy for leprosy patients].  a207-180 v763 a<p>This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages. Combined drugs were diaminodiphenyl sulfone (DDS), rifampicin (RFP) and clofazimine. Clinical evaluation of the treatment after OFLX-combined therapy was remarkable improvement 10 cases, improvement 3 and re-exacerbated after improvement 1 to whom clofazimine and minocycline were prescribed. The evaluation during the follow-up was remarkable improvement 10, improvement 1; three cases died of traffic accident or complications not related to chemotherapy and none of them showed relapse of leprosy. Bacterial negativity after onset of OFLX-combined therapy was achieved in about the same periods as RFP-combined therapy. OFLX-combined therapy was effective and safe. This follow-up study supports the efficacy of clinical guideline for the use of new quinolones published by Japanese leprosy Association.</p>  a1342-3681